Synonyms: hRS7-SN-38-ADC | IMMU-132 | sacituzumab govitecan-hziy | Trodelvy®
sacituzumab govitecan is an approved drug (FDA (2020), EMA (2021))
Compound class:
Antibody
Comment: IMMU-132 is an antibody-drug conjugate (ADC) with SN-38 (the active metabolite of the topoisomerase inhibitor irinotecan) covalently linked to an anti-TROP-2 monoclonal antibody (see patent US8574575 [1]) [2-3,5]. TROP-2 is a transmembrane glycoprotein, cell surface antigen which has oncogenic activity in cancers of epithelial origin [6], but expression is restricted in normal tissue. Directing SN-38 to cancer cells via TROP-2 binding is predicted to limit toxicity towards healthy tissue/cells.
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer | Phase 2 Interventional | Immunomedics, Inc. | ||
NCT02574455 | ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer | Phase 3 Interventional | Immunomedics, Inc. | Approval for TNBC was based on evidence of efficacy from this trial. | |
NCT01631552 | Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers | Phase 1/Phase 2 Interventional | Immunomedics, Inc. |